|Bid||58.91 x 1200|
|Ask||59.30 x 1000|
|Day's Range||58.76 - 59.64|
|52 Week Range||42.48 - 68.34|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||115.28|
|Earnings Date||Aug. 06, 2020|
|Forward Dividend & Yield||1.80 (3.04%)|
|Ex-Dividend Date||Jul. 02, 2020|
|1y Target Est||71.36|
Bristol Myers (BMY) could produce exceptional returns because of its solid growth attributes.
Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.
Top Ranked Growth Stocks to Buy for June 30th
The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. Canada published the final regulations in August last year, despite strong opposition from drug companies.
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndrome
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol Myers Squibb (BMY) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Panic and uncertainty tied to the coronavirus disease 2019 (COVID-19) pandemic initially pushed the broad-based S&P 500 into bear market territory in just 17 trading sessions. As recently as last week, the S&P 500 had bounced more than 40% from its lows and appeared to have established a new bull market. Historically speaking, a correction or crash following a major bounce from a bear market bottom is perfectly normal and expected.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FDA Approves Opdivo for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) ....
Bristol-Myers Squibb (BMY) closed at $60.16 in the latest trading session, marking a -1.26% move from the prior day.
NEW YORK, June 08, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT)..
Investors seeking to beat the market should take a long and hard look at biotech stocks. Here are three top biotech stocks that I think are great picks to buy in June. There's too much to like about Vertex Pharmaceuticals (NASDAQ: VRTX) for it not to top the list.
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.